Neuronetics Inc. (NASDAQ: STIM), a technology firm focused on developing products to enhance the quality of life for patients suffering from mental ailments, recently declared that the FDA has permitted it to start using TouchStar treatment, an intermittent theta-burst (iTBS) protocol with its NeuroStar